Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Recursion Pharmaceuticals, Inc. - Class A Common Stock (NQ:RXRX)

4.499 -0.011 (-0.25%)
Streaming Delayed Price Updated: 3:17 PM EDT, May 20, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 12,519,465
Open 4.500
Bid (Size) 4.490 (55)
Ask (Size) 4.500 (33)
Prev. Close 4.510
Today's Range 4.400 - 4.650
52wk Range 3.790 - 12.36
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Should You Buy This Beaten-Down Artificial Intelligence (AI) Stock on the Dip?
Via The Motley Fool
Topics Animal Testing Artificial Intelligence
Exposures Animal Testing Artificial Intelligence
2 Top Artificial Intelligence (AI) Stocks to Buy Right Now
Via The Motley Fool
Topics Artificial Intelligence
Exposures Artificial Intelligence

Performance

YTD
-37.6%
-37.6%
1 Month
-16.8%
-16.8%
3 Month
-57.7%
-57.7%
6 Month
-26.2%
-26.2%
1 Year
-54.0%
-54.0%

More News

Read More
Why Recursion Pharmaceuticals Stock Plummeted 24% This Week
Via The Motley Fool
Topics Artificial Intelligence Government Stocks
Exposures Artificial Intelligence Political US Equities
Why Recursion Pharmaceuticals Stock Is Plummeting Today
Via The Motley Fool
Topics Artificial Intelligence Government Stocks
Exposures Artificial Intelligence Political US Equities
Recursion to Participate in Upcoming Investor Conferences
From Recursion Pharmaceuticals
Via GlobeNewswire
Earnings Scheduled For May 5, 2025
Via Benzinga
Why Recursion Pharmaceuticals Stock Was Getting Mashed on Monday
Via The Motley Fool
Topics Artificial Intelligence
Exposures Artificial Intelligence
Recursion Reports First Quarter 2025 Financial Results and Provides Business Update
From Recursion Pharmaceuticals
Via GlobeNewswire
Retail Traders Bearish On Recursion Pharma Ahead of Q1 Results Despite Positive Tupelo Trial Data
Via Stocktwits
Topics Earnings
Exposures Financial
Preliminary Phase 1b/2 Data for REC-4881 in Familial Adenomatous Polyposis (FAP) Demonstrates Reduced Polyp Burden
From Recursion Pharmaceuticals, Inc.
Via GlobeNewswire
How Do Investors Really Feel About Recursion Pharmaceuticals?
Via Benzinga
Global Artificial Intelligence Influence on Diabetic Retinopathy Market Expected to See Significant Growth
Via FinancialNewsMedia
Topics Artificial Intelligence
Exposures Artificial Intelligence
Global Artificial Intelligence Influence on Diabetic Retinopathy Market Expected to See Significant Growth
From FN Media Group LLC
Via GlobeNewswire
Recursion to Report First Quarter 2025 Business Updates and Financial Results on May 5th
From Recursion Pharmaceuticals
Via GlobeNewswire
3 Monster Stocks to Hold for the Next 10 Years
Via The Motley Fool
Recursion to Present Preliminary Clinical Data from the Ongoing Phase 1b/2 trial of REC-4881 in FAP at Digestive Disease Week 2025
From Recursion Pharmaceuticals
Via GlobeNewswire
This Beaten-Down Artificial Intelligence (AI) Stock Just Got Some Great News: Time to Buy?
Via The Motley Fool
Topics Animal Testing Artificial Intelligence Intellectual Property
Exposures Animal Testing Artificial Intelligence Intellectual Property
Small Cap News Movers: Your Daily Digest of Stocks Making Moves on Market News
Via Stocktwits
Topics Animal Testing Artificial Intelligence Stocks
Exposures Animal Testing Artificial Intelligence Product Safety
Nvidia-Backed Recursion, Ginkgo Bioworks Rally Following FDA's Decision To End Animal Testing
Via Benzinga
Topics Animal Testing
Exposures Animal Testing Product Safety
Top 3 Biotech Stocks That Got Retail Street Buzzing Last Week: SMMT, PTN, RXRX
Via Stocktwits
Topics Animal Testing
Exposures Animal Testing Product Safety
These Mid-Cap Stocks Outshone The Market Volatility Last Week (Apr 7-Apr 11): Are These In Your Portfolio?
Via Benzinga
The market is filled with gapping stocks in Friday's session.
Via Chartmill
Why Recursion Pharmaceuticals Stock Is Skyrocketing Today
Via The Motley Fool
Topics Animal Testing Artificial Intelligence
Exposures Animal Testing Artificial Intelligence Product Safety
Recursion Pharmaceuticals Shares Are Up Today: what's Going On?
Via Benzinga
Fastenal Posts Better-Than-Expected Sales, Joins Simulations Plus, Certara And Other Big Stocks Moving Higher On Friday
Via Benzinga

Frequently Asked Questions

Is Recursion Pharmaceuticals, Inc. - Class A Common Stock publicly traded?
Yes, Recursion Pharmaceuticals, Inc. - Class A Common Stock is publicly traded.
What exchange does Recursion Pharmaceuticals, Inc. - Class A Common Stock trade on?
Recursion Pharmaceuticals, Inc. - Class A Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Recursion Pharmaceuticals, Inc. - Class A Common Stock?
The ticker symbol for Recursion Pharmaceuticals, Inc. - Class A Common Stock is RXRX on the Nasdaq Stock Market
What is the current price of Recursion Pharmaceuticals, Inc. - Class A Common Stock?
The current price of Recursion Pharmaceuticals, Inc. - Class A Common Stock is 4.499
When was Recursion Pharmaceuticals, Inc. - Class A Common Stock last traded?
The last trade of Recursion Pharmaceuticals, Inc. - Class A Common Stock was at 05/20/25 03:17 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.